Evidence map›Paper›PMID 34017256›Full record

ArticleFrontiers in pharmacology2021

Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against

Xin Li, Yuancheng Chen, Xiaoyong Xu, Yi Li, Yaxin Fan, Xiaofen Liu, Xingchen Bian, Hailan Wu, Xu Zhao, Meiqing Feng and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Xin LiInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Yuancheng ChenPhase I Unit, Huashan Hospital, Fudan University, Shanghai, China.
Xiaoyong XuInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Yi LiInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Yaxin FanInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Xiaofen LiuInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Xingchen BianInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Hailan WuInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Xu ZhaoInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Meiqing FengDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, China.
Beining GuoInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Jing ZhangInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Fudan University · CNHuashan Hospital · CNNational Health and Family Planning Commission · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nemonoxacin, a novel nonfluorinated quinolone for the treatment of community-acquired pneumonia. We reported the pharmacokinetic/pharmacodynamic (PK/PD) targets and PK/PD breakpoints of nemonoxacin against

Indexed as

breakpointnemonoxacinneutropenic murine lung infection modelpharmacokinetics/pharmacodynamicsstreptococcus pneumoniae

Identifiers

PMID34017256
PMCPMC8129567
OpenAlexW3157907178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.